These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 989091)

  • 21. When and how to use heparin prophylaxis and treatment.
    Turpie AG; Hirsh J
    Geriatrics; 1979 Jun; 34(6):59-70. PubMed ID: 447077
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time.
    Basu D; Gallus A; Hirsh J; Cade J
    N Engl J Med; 1972 Aug; 287(7):324-7. PubMed ID: 5041701
    [No Abstract]   [Full Text] [Related]  

  • 23. Continuous heparin infusion requirements. Diagnostic and therapeutic implications.
    White TM; Bernene JL; Marino AM
    JAMA; 1979 Jun; 241(25):2717-20. PubMed ID: 448818
    [No Abstract]   [Full Text] [Related]  

  • 24. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.
    Breddin HK; Hach-Wunderle V; Nakov R; Kakkar VV;
    N Engl J Med; 2001 Mar; 344(9):626-31. PubMed ID: 11228276
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pathophysiology and treatment of deep-vein thrombosis and pulmonary embolism.
    Carter BL; Jones ME; Waickman LA
    Clin Pharm; 1985; 4(3):279-96. PubMed ID: 3891200
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heparin therapy.
    Raich PC; Hahn MF; Korst DR
    Am Fam Physician; 1974 Sep; 10(3):163-8. PubMed ID: 4413661
    [No Abstract]   [Full Text] [Related]  

  • 27. Thrombolysis versus anticoagulation for the initial treatment of moderate pulmonary embolism: a meta-analysis of randomized controlled trials.
    Chen H; Ren C; Chen H
    Respir Care; 2014 Dec; 59(12):1880-7. PubMed ID: 25269681
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevention of venous thromboembolism in the acute treatment phase after spinal cord injury: a randomized, multicenter trial comparing low-dose heparin plus intermittent pneumatic compression with enoxaparin.
    Spinal Cord Injury Thromboprophylaxis Investigators
    J Trauma; 2003 Jun; 54(6):1116-24; discussion 1125-6. PubMed ID: 12813332
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of lower-dose unfractionated heparin for prophylaxis of deep vein thrombosis and pulmonary embolism in an Asian population.
    Ugaki H; Enomoto T; Fujiwara K; Kimura T; Kawasaki T
    Blood Coagul Fibrinolysis; 2008 Sep; 19(6):585-9. PubMed ID: 18685443
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis.
    Hull R; Delmore T; Genton E; Hirsh J; Gent M; Sackett D; McLoughlin D; Armstrong P
    N Engl J Med; 1979 Oct; 301(16):855-8. PubMed ID: 384248
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heparin induced thrombocytopenia: eight cases with thrombotic-hemorrhagic complications.
    Rhodes GR; Dixon RH; Silver D
    Ann Surg; 1977 Dec; 186(6):752-8. PubMed ID: 603279
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin.
    Anand SS; Yusuf S; Pogue J; Ginsberg JS; Hirsh J;
    Circulation; 2003 Jun; 107(23):2884-8. PubMed ID: 12796128
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis.
    Hull R; Delmore T; Carter C; Hirsh J; Genton E; Gent M; Turpie G; McLaughlin D
    N Engl J Med; 1982 Jan; 306(4):189-94. PubMed ID: 7033782
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Different effects of heparin in males and females.
    Campbell NR; Hull RD; Brant R; Hogan DB; Pineo GF; Raskob GE
    Clin Invest Med; 1998 Apr; 21(2):71-8. PubMed ID: 9562927
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk of complications during intravenous heparin therapy.
    Nelson PH; Moser KM; Stoner C; Moser KS
    West J Med; 1982 Mar; 136(3):189-97. PubMed ID: 7090367
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of venous thromboembolism: unfractionated heparin or low molecular weight heparins?
    Agnelli G
    Haematologica; 1995; 80(2 Suppl):78-83. PubMed ID: 7628776
    [No Abstract]   [Full Text] [Related]  

  • 37. [-Anticoagulant drugs-].
    Gulba DC
    Herz; 1996 Feb; 21(1):12-27. PubMed ID: 8647576
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials.
    Davidson BL; Büller HR; Decousus H; Gallus A; Gent M; Piovella F; Prins MH; Raskob GE; Segers AE; Lensing AW;
    J Thromb Haemost; 2007 Jun; 5(6):1191-4. PubMed ID: 17403087
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heparin. Efficacy and safety after arterial operations.
    Collins GJ; Rich NM; Clagett GP; Spebar MJ; Salander JM
    Arch Surg; 1981 Aug; 116(8):1077-81. PubMed ID: 7259513
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
    van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
    Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.